J. Dupin

A multidisciplinary approach to oncology trials: Study conduct of the ANTHALYA trial.

R. Rouzier, F. Joly, Y. Ghazi, 2018, Contemporary clinical trials.

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study

T. Petit, J. Prevost, J. Pierga, 2020, EClinicalMedicine.

Innovative Approach for a Typology of Treatment Sequences in Early Stage HER2 Positive Breast Cancer Patients Treated With Trastuzumab in the French National Hospital Database

J. Lortet-Tieulent, O. Trédan, M. Laurent, 2022, Cancer informatics.

Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.

R. Rouzier, P. Colombo, E. Kalbacher, 2017, European journal of cancer.

PCN190 Kador: A French Retrospective Study Describing the Therapeutic Management of Patients WHO Received Trastuzumab Based Neoadjuvant Treatment for HER2-Positive EARLY Breast Cancer (EBC)

O. Trédan, P. Cottu, D. Pérol, 2020 .

Unresectable hepatocellular carcinoma at dawn of immunotherapy era: real-world data from the French prospective CHIEF cohort

P. Nahon, N. Ganne-Carrié, R. Anty, 2023, European journal of gastroenterology & hepatology.